Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

venetoclax 27fludarabine 26Cyclophosphamide 25Specimen Handling 21Azacitidine 20Biopsy 15Whole-Body Irradiation 14Stem Cell Transplantation 13Decitabine 13Cytarabine 13Tacrolimus 12Melphalan 12fludarabine phosphate 11Mycophenolic Acid 11Busulfan 11Injections 8X-Rays 7Thiotepa 7Hematopoietic Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7decitabine and cedazuridine drug combination 6Cyclosporine 6ruxolitinib 5Magnetic Resonance Spectroscopy 5Idarubicin 5Filgrastim 5gilteritinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic Syndromes × Amsacrine × Clear all
NCT05807932 2024-05-01

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Heinrich-Heine University, Duesseldorf

Phase 1/2 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡